Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate whether dupilumab initiation is associated with reduced short-term flare burden, healthcare utilization, and surgical escalation in pediatric patients with chronic rhinosinusitis with nasal polyps (CRSwNP). STUDY DESIGN: Retrospective cohort study. SETTING: TriNetX United States Collaborative Network. METHODS: Patients aged ≤18 years with chronic rhinosinusitis with nasal polyps were identified between January 1, 2015, and December 31, 2024. Dupilumab-treated patients were indexed at treatment initiation and propensity score-matched 1:1 to nondupilumab controls indexed at a systemic corticosteroid burst based on asthma, atopic dermatitis, allergic rhinitis, and prior endoscopic sinus surgery. Outcomes within 12 months were compared using risk ratios. RESULTS: In 442 matched patients (221 per cohort), dupilumab-treated patients had lower rates of acute sinusitis (12/221 [5.4%] vs 31/221 [14.0%]; risk ratio [RR] 0.39; 95% CI: 0.20-0.73; P = .002), systemic corticosteroid bursts (80/221 [36.2%] vs 101/221 [45.7%]; RR 0.79; 95% CI: 0.63-0.99; P = .042), and functional endoscopic sinus surgery (19/221 [8.6%] vs 38/221 [17.2%]; RR 0.50; 95% CI: 0.30-0.84; P = .007). Nasal polyp diagnoses were more frequently documented in the dupilumab-treated cohort (148/221 [67.0%] vs 95/221 [43.0%]; P < .0001), while emergency department visits (16/221 [7.2%] vs 27/221 [12.2%]; P = .078) and inpatient admissions (12/221 [5.4%] vs 16/221 [7.2%]; P = .435) were similar between cohorts. CONCLUSION: These findings suggest that dupilumab may be a steroid-sparing and surgery-sparing option in pediatric CRSwNP.
No takes yet. Share an insight, caveat, or question.
Haji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: